ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

obicetrapib

Also written as “TA-8995”, “Obicetrapib” and “Obicetrapib 10 mg”.

Its studies are mostly in Dyslipidemias · Hypercholesterolemia · Alzheimer Disease · Hyperlipidemias · Atherosclerosis, led by 3 companies.

Drug pageTA-8995: every studyAll 27 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 18, 202127 company-led studies, 7 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
NewAmsterdam Pharma197 open or runningphase 3since Nov 18, 2021Feb 9, 2021Nov 2026phase 2 · NCT06496243
Xentionits history only60 open or runningphase 2since Oct 21, 2013Oct 21, 2013none ahead
Tanabe Pharmaits history only20 open or runningphase 1since Jun 4, 2013Jun 4, 2013none ahead

Also a collaborator on its studies: Pharma Medica Research and Novum.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of NewAmsterdam Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 5 earlier studies, Feb 9, 2021 to Nov 23, 2021.

  1. Jun 9, 2016Named obicetrapibINNProposed as its International Nonproprietary Name in WHO's List 115 · before, TA-8995
  2. Feb 23, 2022Phase 2 study in DyslipidemiasNCT05266586 · 119 enrolled · United States
  3. Jun 13, 2022Phase 2 study in DyslipidemiasNCT05421078 · 102 enrolled · Japan
  4. Jun 15, 2022Phase 3 study in DyslipidemiasNCT05425745 · 354 enrolled · United States, Canada, Czechia and more
  5. Jul 25, 2023Phase 1 study in Lipid MetabolismNCT05972278 · 22 enrolled · United States
  6. Aug 15, 2023Phase 3 study in DyslipidemiasNCT06005597 · 407 enrolled · United States
  7. Aug 29, 2023Phase 1 study in Hepatic ImpairmentNCT06048302 · 18 enrolled · United States
  8. Oct 3, 2023Phase 1 study in Healthy VolunteersNCT06081166 · 74 enrolled · Canada
  9. Feb 1, 2024Phase 1 study in Healthy VolunteersNCT06250205 · 30 enrolled · United States
  10. Feb 28, 2024Phase 3 study in HyperlipidemiasNCT06305559 · 300 enrolled · United States
  11. Jul 3, 2024Phase 2 study in DyslipidemiasNCT06496243 · 69 planned · United States
  12. Aug 1, 2024Phase 1 study in Healthy VolunteersNCT06547359 · 94 enrolled · Canada
  13. May 13, 2025Phase 2 study in Antioxidant AbsorptionNCT06982508 · 100 planned · United States
  14. Oct 20, 2025Phase 3 study in HyperlipidemiasNCT07219602 · 300 enrolled · United States, Czechia, Netherlands and more
  15. Aug 12, 2026Phase 2 study in Alzheimer DiseaseNCT07794670 · 400 planned · United States

Ahead

  1. Nov 2026Primary completion: phase 2 study in DyslipidemiasNCT06496243
  2. Nov 2026Primary completion: phase 3 study in AtherosclerosisNCT05202509
  3. Nov 2027Primary completion: phase 3 study in HyperlipidemiasNCT06305559
  4. Mar 2028Primary completion: phase 3 study in HyperlipidemiasNCT07219602

TargetBeta

CETP →read by rule
“Cholesteryl ester transfer protein inhibitor”ChEMBL 37, by rule

Studies

All 19 NewAmsterdam Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07794670Alzheimer Disease · United States2RecruitingSep 2028400
NCT07219602Hyperlipidemias · United States, Czechia, Netherlands and more3Active, not recruitingMar 2028300
NCT06982508Antioxidant Absorption · United States2RecruitingSep 2026100
NCT06547359Healthy Volunteers · Canada1CompletedNov 12, 202494
NCT06496243Dyslipidemias · United States2RecruitingNov 202669
NCT06305559Hyperlipidemias · United States3Active, not recruitingNov 2027300
NCT06250205Healthy Volunteers · United States1CompletedApr 25, 202430
NCT06081166Healthy Volunteers · Canada1CompletedDec 2, 202374
NCT06048302Hepatic Impairment · United States1CompletedMar 12, 202418
NCT06005597Dyslipidemias · United States3CompletedSep 25, 2024407
NCT05972278Lipid Metabolism · United States1Active, not recruitingSep 26, 202422
NCT05425745Dyslipidemias · United States, Canada, Czechia and more3CompletedMay 28, 2024354
NCT05421078Dyslipidemias · Japan2CompletedMar 24, 2023102
NCT05266586Dyslipidemias · United States2CompletedAug 12, 2022119
NCT05161715Alzheimer Disease · Netherlands2CompletedMay 9, 202313
NCT05202509Atherosclerosis · United States, Australia, Bulgaria and more3Active, not recruitingNov 20269,541
NCT05142722Dyslipidemias · United States, China, Czechia and more3CompletedSep 26, 20242,530
NCT04770389Dyslipidemias · United States, Netherlands2CompletedMay 7, 2021112
NCT04753606Dyslipidemias · United States2CompletedMay 24, 2021120

How it is read

Names in the registry

  • “TA-8995”, 16 entries
  • “Obicetrapib”, 11 entries
  • “Obicetrapib 10 mg”, 2 entries
  • “obicetrapib 10 mg + ezetimibe 10 mg FDC daily”, 2 entries
  • “Obicetrapib 10mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.